The STEP 1 trial extension the largest semaglutide follow-up study found that participants regained roughly two-thirds of their prior weight loss within 52 weeks of stopping the drug
GHK-Cu, with its documented effects on connective tissue repair, anti-inflammatory regulation, and nerve growth factor stimulation, fills the recovery support role
Two other pharmaceutical companies have their own oral GLP-1 drugs in the works: Orforglipron: Developed by Eli Lilly, its in Phase 3 clinical trials for treating type 2 diabetes and obesity, with an expected September 2025 completion
No discontinuation was observed among CGRP mAb users
Our team helps clients assess risk and make informed decisions grounded in current law and enforcement trends
Indeed, in one series there was no difference in the distribution of hematocrit values in cord blood and on day 3 between G6PD-deficient newborns with and without jaundice, thus suggesting that to a large extent this jaundice may be of hepatic origin rather than hemolytic
